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Summary: Stratification of haematology patients according to clinical, genetic and mycological risk 17 
of invasive aspergillosis (IA) showed   50% of patients were low risk (<5%) for IA, and <10% were at 18 
>50% risk. Personalized medicine provides a strategic approach for managing IA.19 
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ABSTRACT 20 
The incidence of invasive aspergillosis (IA) in high risk haematology populations, is relatively low 21 
(<10%), despite unavoidable exposure Aspergillus in patients with potentially similar clinical risk. 22 
Non-clinical variables including genetic mutations that increase susceptibility to IA could explain why 23 
only certain patients develop disease. This study aimed to screen for mutations in 322 haematology 24 
patients classified according to IA status, and to develop a predictive model based on genetic risk, 25 
established clinical risk factors and diagnostic biomarkers. 26 
Genetic markers were determined by real-time PCR, and with clinical risk factors and Aspergillus PCR 27 
results were analysed by multi-logistic regression analysis to identify a best-fit model for predicting 28 
IA. Probability of IA was calculated and an optimal threshold determined. 29 
Mutations in Dectin-1 (rs7309123) and DC-SIGN (rs11465384 and rs7248637), allogeneic stem cell 30 
transplantation, respiratory virus infection and Aspergillus PCR positivity were all significant risk 31 
factors for developing IA and combined in a predictive model. An optimal threshold requiring three 32 
positive factors generated a mean sensitivity/specificity of 70.4%/89.2%, and a probability of 33 
developing IA of 56.7%. In patients with no risk factors the probability of developing IA was 2.4%, 34 
compared to >79.1% in patients with four or more factors. Using a risk threshold of 50%, pre-35 
emptive therapy would have been prescribed in 8.4% of the population. 36 
Summary 37 
This pilot study shows that patients can be stratified according to risk of IA, providing personalized 38 
medicine, based on strategic evidence, for the management of IA. Further studies are required to 39 
confirm this approach. 40 
41 
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INTRODUCTION 42 
The limited ability to accurately diagnosis invasive aspergillosis (IA) has led to an overreliance on 43 
empirical antifungal therapy (1). In recent years the incorporation of highly sensitive non-culture 44 
diagnostics (PCR, galactomannan EIA (GM) aŶd β-D-Glucan) has increased diagnostic accuracy 45 
enabling disease to be excluded, decreasing unnecessary antifungal use (2-4).Early diagnosis is 46 
important for good prognosis and pre-emptive approaches, utilising non-culture based tests, can 47 
provide early evidence of infection (2-5). However, biomarkers alone are insufficient to initiate 48 
therapy as false positive results occur. Biomarkers are best used to exclude disease when negative, 49 
with positivity used to trigger further clinical investigations (e.g. Bronchcoscopy and HRCT) to 50 
confirm disease. 51 
A pre-emptive strategy of managing IA may have advantages.  By definition a pre-emptive approach 52 
involves taking action against an anticipated outcome, dependent on the likelihood of the patient 53 
developing future disease as determined by risk factors. While this is similar to a prophylactic 54 
strategy it differs due to the availability of sensitive biomarker assays, and the necessity for 55 
biomarker positivity during the early infective processes, prior to clinically overt disease. The 56 
threshold at which pre-emptive action is taken is critical; too low and the number of patients treated 57 
may be comparable empirical policies, too stringent and the opportunity to prevent disease is 58 
missed. Thresholds can be dynamic, dependent on perceived and potential outcomes of which may 59 
also alter the risk. 60 
There are multiple risk factors for IA in the haematology population (6-8). Many are associated with 61 
the underlying haematological malignancy and treatment, including prolonged neutropenia, 62 
lymphopenia, allogeneic stem cell transplantation (SCT), iron overload, graft-versus-host disease 63 
(GVHD), prolonged corticosteroid use, monoclonal antibody use. Infection by other microbes (CMV 64 
and/or respiratory viruses), can also increase the risk of IA. Exposure to Aspergillus is unavoidable, 65 
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but exposure to high levels of the organism during building construction or housing in contaminated 66 
environments increases risk of disease. 67 
Recently, genetic predisposition has been recognized as a risk factor for fungal infection. Research 68 
has focused on specific nucleotide polymorphisms (SNPs) in genes coding for proteins involved in 69 
innate and adaptive immune responses. C-type lectin receptors (Dectin-1, Dectin-2, Mannose 70 
binding lectin, DC-SIGN and Mincle)
 
play a primary role in fungal immunity and much research has 71 
concentrated on these targets (9). Mutations in other pattern recognition receptors (Toll Like 72 
receptors TLRs) have also been associated with increased risk of IA (10). These genetic risk factors 73 
although relatively non-specific are present before infection and provide an opportunity to stratify 74 
patients according to risk. Risk factor stratification may improve patient management but requires a 75 
combination of host, clinical and early diagnostics markers. 76 
Non-culture diagnostic assays can detect early infective processes, and the aim is to detect infection 77 
before overt tissue damage occurs.  GM is mainly released from actively growing hyphae and 78 
presence in the circulation indicates hyphal growth and invasion (11).
 
Aspergillus PCR has been 79 
shown to be positive earlier than GM and (1-3)-β-D-Glucan (2, 12, 13). In an animal model of IA, 80 
blood was Aspergillus PCR positive at a time scale that related to exposure rather than disease (13). 81 
While this may reduce PCR specificity it may be more beneficial in pre-emptive roles in patients 82 
stratified according to risk.  83 
The aim of the study was not to identify novel clinical and genetic risk factors for IA, but, more so, 84 
combine risk factors previously associated with the disease, along with a well validated and 85 
Aspergillus PCR assay, standardized according to international recommendations, into a predictive 86 
model to determine the probability of developing IA. Genetic markers in Dectin-1 and DC-SIGN 87 
previously associated with IA, were retrospectively combined with established clinical risk factors 88 
and Aspergillus PCR screening results in a cohort of high risk patient to determine whether a 89 
management strategy could stratify patients according to risk, providing personalised medicine to 90 
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pre-empt disease (14). 91 
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MATERIALS AND METHODS 92 
Patient population and study design 93 
As part of the local neutropenic fever care pathway, haematology patients are routinely monitored 94 
for invasive fungal disease (IFD) by PCR and GM (2, 15). Patients were included on the certainty of 95 
diagnosis assigned by the EORT-MSG criteria (16). If patients were defined as proven, probable or 96 
possible IA they were included as cases. If patients had absolutely no radiological or mycological 97 
evidence of IA they were included as controls. Subsequently, patients with non-specific radiology 98 
and mycological evidence were excluded in order to maintain definitive case/control categorization. 99 
Retrospectively, a total of 322 haematology patients were anonymised and stratified according to IA 100 
diagnosis, using the revised EORTC-MSG definitions (16).There were 6 proven IA, 48 probable IA, 20 101 
possible IA and 268 patients with no evidence of fungal disease (NEF). Given the lower certainty of 102 
diagnosis cases of possible IA were excluded from statistical analysis. Patients were treated for 103 
malignancy and other haematological /autoimmune conditions between October 2005 and June 104 
2009. Known risk factors for developing IA were linked to the disease (Table 1.). As all patients are 105 
screened as part of the neutropenic fever care pathway neutropenia or fever were not included as 106 
risk factors. Information on underlying disease, clinical course (SCT, GVHD, and other infections), 107 
radiological history, results of all IA biomarkers, and mortality was gathered as part of the routine 108 
clinical management. No additional information outside this remit was sought. Clinical features 109 
(Histology/HRCT) or mycological (GM /culture) evidence used to define disease within consensus 110 
criteria were not included as risk factors to avoid incorporation bias.  111 
The presence of SNPs, previously associated with increased risk of IA, was determined (14). SNPs 112 
were chosen on their availability as commercially available TaqMan assays, providing both 113 
methodological simplicity and standardisation, and quality control. The SNP assays were 114 
retrospectively performed on stored genomic DNA, previously extracted as bi-product of Aspergillus 115 
PCR screening. No additional samples specific for this purpose were requested and the local ethics 116 
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board ruled the project did not require ethical approval and was approved by the research and 117 
development board.118 
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Galactomannan EIA testing 119 
Testing by Platelia Aspergillus EIA (Bio-RadͿ ǁas uŶdeƌtakeŶ as peƌ the ŵaŶufaĐtuƌeƌ’s iŶstƌuĐtioŶs. 120 
Optical densities (OD) were read at 450/620nm (Thermo Scientific Multiscan FC). Indices were 121 
calculated by dividing the OD of the sample by the mean OD of two threshold controls included in 122 
the kit. All samples were ĐoŶsideƌed positiǀe if the saŵple iŶdeǆ ǁas ≥0.5. 123 
 124 
Aspergillus PCR testing 125 
Molecular testing was performed as previously described using well established methods that were 126 
compliant with international recommendations (2, 15, 17).
 
In brief, DNA was extracted from a 127 
minimum of 3ml EDTA whole blood subjected to red and white cell lysis, prior to bead-beating and 128 
followed by automated DNA purification/precipitation using the Qiagen EZ1. Both human and 129 
Aspergillus DNA, when present, are co-extracted. Aspergillus PCR targeted the 28S rRNA gene with a 130 
limit of detection 3 input copies per reaction, and an internal control was used to monitor for 131 
inhibition. Clinical performance of the PCR has been previously described (15, 18).
 
132 
 133 
Determination of genetic risk factors 134 
A total of five SNPs previously associated with IA were available as commercially sourced TaqMan 135 
SNP assays (Applied Biosystems) (Table 2) (14, 19). Genomic DNA was extracted as a bi-product of 136 
routine Aspergillus PCR testing as described above. Prior to testing the concentration and quality 137 
(A260/A280 ration) of the extracted DNA was determined by nanophotometer (P-300 138 
nanophotometer, Implen, Germany). GeŶotǇpiŶg ǁas peƌfoƌŵed as peƌ ŵaŶufaĐtuƌeƌ’s 139 
recommendations using an ABI7500 fast instrument.  140 
Each sample was anonymously tested in duplicate, when sufficient DNA was available. For patients 141 
undergoing allogeneic SCT one sample prior to and one sample several weeks after SCT were tested. 142 
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If discordant results were generated additional samples, pre and post SCT, were tested to confirm 143 
genotypic switch post SCT.  144 
 145 
Statistical analysis 146 
Genotype and clinical risk factor frequencies were compared between proven/probable IA and NEF 147 
gƌoups ǁith the use of Fisheƌ’s eǆaĐt test aŶd PeaƌsoŶ 2 tests. Odds ratios (OR) and 95% confidence 148 
intervals (CI) were calculated for the presence (combined homozygous/heterozygous SNP) or 149 
absence (homozygous wild-type allele) of the polymorphisms and clinical risk factors. The thresholds 150 
for significance for clinical and genetic risk factors were separately adjusted for multiple variables by 151 
performing the Bonferroni adjustment method (Clinical factors Significance P: 0·0125, Genetic 152 
factors significance P: 0·01). Pair-wise logistic regression was used to identify any associations 153 
between independently significant risk factors and when necessary adjustments were performed by 154 
Mantel-Haenszel OR and 2 test of heterogeneity used to determine the significance of the 155 
adjustment. For each SNP consistency with the Hardy-Weinberg Equilibrium was determined by a 156 
standard observed-expected 2 tests with P value at 1 degree of freedom. In order to determine any 157 
genetic linkage between significant SNPs linkage disequilibrium was calculated and an exclusion 158 
threshold of r
2
 ≥0·8 was set. In order to provide a clinical utility the probability of IA post-risk factor 159 
was also calculated. Receiver operator characteristic (ROC) analysis was performed to determine an 160 
optimal threshold for the final model. 161 
162 
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RESULTS 163 
Genetic markers and IA 164 
Three SNPs (Dectin-1 rs7309123, DC-SIGN rs11465384 and DC-SIGN rs7248637) showed a significant 165 
correlation with proven/probable IA (Table 2).  All five SNPs were consistent with Hardy-Weinberg 166 
equilibrium. Linkage disequilibrium (LD) analysis showed that SNPs rs11465384 and rs7248637 were 167 
in LD with each other (r
2
 = 0·6) but did not reach the pre-requisite threshold (r
2
 ≥0·8) for exclusion  168 
Given the association between DC-SIGN rs11465384 and DC-SIGN rs7248637 (OR: 54·3, 95% CI:  169 
22·8-129·2, P: <0·0001) it was decided to consider them a haplotype and combine data for further 170 
analysis; the association with IA remained significant (OR: 3·0, 95% CI: 1·6-5·7, P: 0·0011). Logistic 171 
regression identified only limited associations between clinical risk factors and genetic markers and 172 
the data was adjusted accordingly (Table 2). There were no associations between any of the SNPs 173 
and other infections (CMV/respiratory virus) included in the study.  174 
As individual assays, none of the significant SNPs could be used to confidently diagnose (highest 175 
positive likelihood ratio (LR +tive): 2·48) or exclude IA (lowest negative likelihood ratio (LR –tive): 176 
0·37). Even if all three significant SNPs were present in an individual (9·0% of the population) the LR 177 
+tive for developing IA was only 4·0, and if they were negative for all significant SNPs (27·6% of the 178 
population) the LR -tive was 0·2.  179 
A multivariate regression model (Model fit P: 0·0003) of genetic markers factors confirmed 180 
significant associations between the DC-SIGN haplotype (P: 0·0126) and Dectin-1 rs7309123 (P: 181 
0·0035) and the development of IA. These were retained for inclusion in the final model. 182 
 183 
Clinical risk factors for IA 184 
The analysis in this population confirmed previous findings. Significant associations between IA and 185 
acute leukaemia/myelodysplastic syndrome (AL/MDS OR: 2·095 CI: 1·115-3·941), use of allogeneic 186 
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SCT (OR: 2·90, CI: 1·25-6·69) and infections with respiratory viruses (OR: 3·22, CI: 1·44-7·21), mainly 187 
driven by respiratory syncytial virus infection (OR: 3·47, CI: 1·38-8·69) (Table 1.). 188 
From table 1 it is evident that there is a difference in age between patients with proven/probable IA 189 
and those with NEF, but when adjusting for allogeneic SCT, this was not significant. The same was 190 
true for CMV infection and GVHD where initial analysis showed a significant association with IA 191 
(CMV: OR: 4·301 CI: 1·929-9·561, P: <0·0001; GVHD OR: 10·07, CI: 3·78-27·3, P: <0·0001), but this 192 
was removed after adjustment for SCT. Respiratory virus infections retained a significant 193 
independent associated with IA even after adjustment (Table 1). 194 
A multivariate regression model (Model fit P: <0·0001) of clinical factors confirmed significant 195 
associations between developing IA and patients diagnosed with AL/MDS (P: 0·0314), patients 196 
receiving allogeneic SCT (P: 0·0021) and patients with respiratory virus infection (P: 0·0043). The 197 
odds of developing IA when associated with the various significant clinical factors are shown in Table 198 
3. For the AL/MDS population allogeneic SCT and respiratory virus infection were again significantly 199 
associated with IA. For the non AL/MDS population allogeneic SCT remained significant whereas 200 
respiratory virus infection was not significant, albeit numbers were limited. The following variables, 201 
underlying haematological disease, allogeneic SCT and respiratory virus infection, were retained for 202 
inclusion in the final model.  203 
 204 
Aspergillus PCR  205 
The sensitivity, specificity, LR +tive, LR –tive and DOR for Aspergillus PCR using a single positive result 206 
as significant were 92·6% (95% CI: 82·0-97·6), 65·3%, (95% CI: 63·2-66·3), 2·7, 0·1 and 27, 207 
respectively. Although there was a strong association between PCR result and IA status (OR: 23·5 208 
95% CI: 7·8-79·2, P: <0·0001) PCR can be used to confidently exclude IA but diagnosis is hampered by 209 
false positivity. Using a multiple positive PCR threshold significantly increased specificity (85·4%, 95% 210 
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CI: 83·0-87·3), although it still could not be used solely to confirm a diagnosis of IA (LR +tive: 5·3). 211 
Aspergillus PCR testing was retained for inclusion in the final model.  212 
 213 
Combined prediction Model 214 
In determining the final model clinical risk factors (underlying haematological malignancy (AL/MDS ), 215 
Allogeneic SCT , respiratory virus infection),  presence of significant genetic markers (DC-SIGN 216 
haplotype and Dectin-1 rs7309123), and mycological evidence not used to categorise IA disease 217 
(Aspergillus PCR result) were combined.  218 
On combination of these variables, underlying haematological malignancy was no longer significantly 219 
associated with IA (P: >0·5772) and was removed from the model. The final model fit was 2: 106·4 220 
(P: <0·0001). The probability of developing IA associated with various combinations of clinical risk 221 
factors, genetic markers and biomarker positivity is shown in Figures 1a and 1b. For patients not 222 
receiving, or prior to, an allogeneic SCT the risk of developing IA, even in the presence of genetic 223 
markers was low (<5%). Consequently, 59·6% (162/272) of the patients without allogeneic SCT could 224 
be considered low risk and only patients with multiple genetic markers, who were Aspergilus PCR 225 
positive and had a respiratory virus infection (1·8% (5/272) of this population), had a risk of IA that 226 
exceeded 50% (Figures 1a and Figure 2).  227 
The majority (96%) of patients post-allogeneic SCT were at greater risk of IA (>5%), with significantly 228 
higher risk (>50%) in 44% (22/50) of allogeneic SCT patients who were both Aspergillus PCR positive 229 
and had a respiratory infection, or who had multiple genetic markers and were either Aspergillus 230 
PCR positive or had a respiratory infection (Figures 1b and Figure 2). The risk of IA in 10% (5/50) of 231 
allogeneic patients with multiple genetic markers who were PCR positive and had respiratory virus 232 
infection was 89·9%. 233 
When applying this model to the entire haematology population (n=322) 50·9% would be considered 234 
at low (<5%) and 8·4% at high (>50%) risk of developing IA. A breakdown of risk is shown in Figure 2.  235 
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ROC analysis of the final model generated an AUC of 0·8633 (Figure 3). If one variable was positive 236 
the sensitivity was 98·2% (95% CI; 90·1-99·9) and the LR-tive was 0·12, whereas if four or more 237 
variables were positive the specificity was >98·15 (95% CI: 95·7-99·4) and the LR+tive >18·8. The 238 
mean probability of developing IA in a patient with four risk factors was 79.2%. The optimal 239 
threshold to start pre-emptive therapy required three variables to be positive and the sensitivity and 240 
specificity were 70·4% (95% CI: 56·4-82·0) and 89·2% (95% CI: 84·8-92·6). The corresponding positive 241 
and negative likelihood ratios were 6.50 and 0.332 and in patients with three risk factors the mean 242 
probability of developing IA was 56.7%, compared to 6.3% in patients with <3 risk factors present. 243 
The number needed to treat was 1.69 (95% CI: 1.6-2.6). Using a threshold of two risk factors positive 244 
the sensitivity and specificity of the model were 90·7% (95% CI: 79·7-96·9) and 62·3% (95% CI: 56·2-245 
68·1) and the positive and negative likelihood ratios were 2.41 and 0.149, respectively. The mean 246 
probability of developing IA in patient with 32.6%, compared to 2.9% in patients with <2 risk factors 247 
present. 248 
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DISCUSSION 249 
The purpose of this study was to develop a model combining genetic markers with established 250 
clinical risk factors and biomarker screening to stratify haematology patients at risk of developing IA. 251 
By linking the high sensitivity of PCR testing (Sensitivity: 92·6%, LR-tive: 0·11) with specificity driven 252 
by combined clinical factors and genetic susceptibility (Pair-wise specificity range: 94·0-99·6; LR+tive: 253 
6·2-37) (Figures 1a/1b) diagnostic performance is improved. ROC analysis showed the model was 254 
able to both exclude and diagnose IA (Figure 3). Using the optimal threshold of three positive risk 255 
factors generated the mean probability of developing IA across the combined haematology 256 
population was 56.7%. However, the probability of developing IA varied according to the 257 
combination of the three risk factors and in non-allogeneic patients (already missing one risk factor) 258 
the presence of four risk factors (Both genetic markers, Aspergillus PCR positivity and respiratory 259 
virus infection) were required to achieve a risk greater than 50% (N=5 patients). In this population 260 
the risk associated with three risk factors ranged from 14.1% to 45.5% (Figure 1a). If a minimum of 3 261 
risk factors were required the mean probability of developing IA in the non-allogeneic population 262 
alone was 48.9%. In the allogeneic population the probability of IA developing IA when a patient had 263 
three risk factors ranged from 17.9% to 52.5% (Figure 1b). For the allogeneic population alone the 264 
mean probability of developing IA using a threshold of at least three positive risk factors was 63.9%. 265 
If at least four risk factors were required the probability of developing IA in the allogeneic population 266 
alone was 83.3%.  267 
When combining the significant variables it was decided to take a strategic approach based on the 268 
probable timeline of evidence available in the clinic. SNP analysis could identify patients with genetic 269 
susceptibility to IA who could benefit from disease preventative strategies (either mould active 270 
prophylaxis or PCR/GM screening and pre-emptive treatment). Alternatively, a low probability of IA 271 
(<5%), could lead to a diagnostic approach with biomarker testing only when disease was clinically 272 
suspected.  273 
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In this study 41 SCT patients changed alleles in loci where SNPs were significantly associated with IA 274 
(Figure 4). Nineteen patients had SNPs removed post SCT and five developed IA, whereas 22 patients 275 
had SNPs introduced post SCT and significantly more (17, P: 0·0017) developed IA. Further studies 276 
are needed but this suggests the need to screen either donors or patients post SCT to determine 277 
risk. There is potential to remove high-risk SNPs by finding a suitable donor and to prevent the 278 
introduction of SNPs in patients with wild-type alleles pre-SCT. 279 
Post SCT the presence of high-risk SNPs increased the risk of IA >5% and biomarker screening is 280 
required (Figure 2). If the patient is subsequently PCR positive, the risk of IA exceeds 48%, and 281 
respiratory virus infection increased this further to >75·9%. These patients should be screened by 282 
PCR /GM and treated pre-emptively to reduce associated mortality due to delayed diagnosis of IA 283 
disease (20).
 
284 
Choosing optimal genetic markers can be difficult. Many have ethnic or geographical linkage and 285 
maybe unique to local population, limiting the widespread potential of the generic strategies. The 286 
SNPs used in this study, targeting a ≈95% Caucasian Welsh population (n=322, IA=54) confirm the 287 
findings of a previous Spanish study (n=182, IA=57) (14).
 
Further confirmation of the applicability of 288 
these SNPs in additional ethnicities is required, and the application of novel SNPs must be 289 
investigated. Genome wide association studies  and high throughput next generation sequencing will 290 
identify further SNPs associated with the IA and provide large amounts of specific information with 291 
minimal effort.  292 
The DC-SIGN SNPs in both this and the previous Spanish study were associated with IA, but it is 293 
important to exclude the possibility of confounding factors (14).DC-SIGN is reported to have roles in 294 
HIV, Hepatitis C and CMV (21-23).
 
This current study found no correlation between CMV infection 295 
and the presence of either DC-SIGN SNP (rs114 P: 0·9314 and rs724 P: 0·4370), but larger studies are 296 
needed. The heterogeneity of the patient population, but more so the limited number of certain 297 
clinical conditions, including allogeneic stem cell transplant, will limit the ability of the study in 298 
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determining all risk factors. Large scale multi-centre centres targeting specific populations (e.g. 299 
transplant versus no-transplant) are required in order to determine conclusive findings.  A further 300 
limitation of the study is the limited number of proven cases (n=6). However, the number of 301 
probable cases compensates for this and while the level of confidence of diagnosis is less than that 302 
for proven IA, it highlights the difficulty in diagnosing IA and represents the usual level of diagnosis 303 
attained in the clinical setting. Furthermore, cases of probable IA are regularly accepted in clinical 304 
trials of antifungal therapy and their inclusion is equally applicable in this current study. PCR is 305 
currently excluded from the revised EORTC/MSG definitions for IFD (16). Data from the audit of this 306 
cohort showed most possible IA cases (GM negative be definition) to be Aspergillus PCR positive (2) 307 
The likely inclusion of PCR in the second revision of the definitions will therefore increase the 308 
number of probable cases in this study, but also provide an alternative mycological criterion allowing 309 
us to incorporate GM testing into the model without the concern of incorporation bias.  310 
In conclusion, this proof of concept study shows that genetic markers in combination with clinical 311 
risk and early biomarker positivity can facilitate stratification of patients according to risk of IA.  If 312 
the probability of developing IA passes 50% then the use of pre-emptive therapy is justified and in 313 
this study only 8.3% (27/322) of the population, mainly allogeneic patients (n=22) would receive 314 
therapy (Figure 2). It highlights what can be achieved to improve management of patients at risk of 315 
difficult to manage fungal diseases, and is an attempt to translate pre-clinical research into a clinical 316 
setting (24). For this type of approach to be of use, it must be easily accessible, dynamic to change 317 
and simple to use with respect to data input and processing. These systems can be applied to 318 
portable electronic devices to permit real-time clinical decision making, individual patient 319 
management and a strategic evidence based approach to the management of IA, or other difficult to 320 
diagnose diseases. Further studies are needed to determine the range of genetic markers associated 321 
with IA and while a recent large scale study by Fisher et al. investigated the relevance of previously 322 
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documented SNPs using micro-array the application of whole genome sequencing will be essential 323 
for this purpose (25). 324 
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Table 1. Patient demographics, underlying disease, haematopoetic stem cell transplantation 427 
status, biomarker (PCR) positivity and additional viral infections stratified by invasive 428 
aspergillosis (IA) classification. Any significant differences between proven/probable IA and 429 
patients with no evidence of fungal disease are highlighted in bold text. 430 
 
 
Parameter 
Disease classification  
Significance
f
 
(proven/probable vs NEF) 
 
Proven (n=6) 
Probable 
(N=48) 
Possible 
(N=20) 
 
NEF (N=268) 
Ratio male/female 
 
2:1 1.7:1 1.9:1 1.5:1 P: 0·7667 
Median Age (years) 58 52 64 61 P: 0·31
g 
Underlying disease (n) 
Acute leukaemia/MDS  
Lymphoma 
Myeloma 
Chronic Leukaemia 
Other
a
 
 
3 
1 
1 
1 
0 
 
25 
13 
4 
4 
2 
 
15 
3 
0 
2 
0 
 
91 
90 
50 
18 
19 
 
P: 0·011 
P: 0·3389 
P: 0·1134 
P: 0·5605 
P: 0·5521 
Mortality (%) 
 
66.7 54.2 60.0 45.5 P: 0·1302 
Transplant rate (%) 
Combined 
Allogeneic 
Autologous 
No transplant 
 
 
50.0 
50.0 
0.0 
50.0 
 
58.3 
45.8 
12.5 
41.7 
 
20.0 
20.0 
0.0 
80.0 
 
33.6 
9.3 
24.3 
66.4 
 
P: 0·0018 
P:<0.0001
h
 
P: 0·00321 
P: 0·0018 
 
GVHD (n) 
 
2 12 2 9 P:0·2757
i 
PCR positivity (n)  
1positive threshold
b 
≥2 positiǀe thƌesholdc 
 
6 
6 
 
44 
36 
 
15 
10 
 
93 
39 
 
P:<0·0001 
P:<0·0001 
 
Additional infections      
CMV (n) 4 11 3 22 P:0·3494
j 
 
Respiratory Virus (n) 
Influenza A or B 
Parainfluenza 
Rhinovirus 
RSV 
Adenovirus 
 
Patients with multiple 
respiratory virus 
infections
 
1 
0 
1 
0 
0 
0 
 
0 
 
34 
9 
7 
5 
12 
1 
 
8
d 
4 
1 
1 
0 
2 
0 
 
0 
38 
11 
8 
10 
9 
0 
 
8
e  
P: 0·0025
k
 
P: 0·2113
k
 
P: 0·0988
k
 
P: 0·4879
k
 
P: 0·0046
k 
P: 0·2996
k
 
 
P: 0·1483
k 
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a 
Includes: 8 cases of aplastic anaemia, 3 cases of myelofibrosis, 3 cases of unspecified leukaemia, 2 431 
cases of Paroxysmal nocturnal hemoglobinuria, 2 cases of unspecified haematological malignancy, 1 432 
case of amyloidosis, 1 case of unspecified autoimmune disorder, 1 case of IGM paraproteinanaemia , 433 
and 1 case of post transplant lymphoproliferative disorder. 434 
b 
A single PCR positive result is considered significant. 435 
c Multiple ;≥2Ϳ PCR positiǀe ƌesults aƌe ƌeƋuiƌed to ďe ĐoŶsideƌed sigŶifiĐaŶt. 436 
d 
Includes: 20 infections from eight cases of proven/probable IA. Multiple infections include: 2 cases 437 
with influenza/parainfluenza, 1 case with Adenovirus/Rhinovirus, 1 case with 438 
influenza/parainfluenza/RSV/rhinovirus, 1 case with influenza/RSV/rhinovirus, 1 case with 439 
influenza/rhinovirus, 1 case with parainfluenza/rhinovirus and 1 case with 440 
influenza/parainfluenza/rhinovirus. These multiple infections are included in the individual 441 
breakdown of respiratory virus infection.  442 
e 
Includes: 18 infections from eight cases with no evidence of invasive fungal disease. Multiple 443 
infections include: 4 cases with parainfluenza/rhinovirus, 1 case with influenza/parainfluenza/RSV, 1 444 
case with influenza/RSV/rhinovirus, 1 case with influenza/parainfluenza and 1 case with 445 
RSV/rhinovirus. These multiple infections are included in the individual breakdown of respiratory 446 
virus infection. 447 
f 
Significance adjusted to 0·0125 according the Bonferroni adjustment method to account for the 448 
presence of 4 potential risk factors (underlying disease, stem cell transplantation, GVHD and viral 449 
infection). 450 
g 
Adjusted to account for association with allogeneic stem cell transplantation, GVHD and respiratory 451 
virus status. 452 
h
 Adjusted to account for associations with GVHD, CMV and respiratory virus status 453 
i 
Adjusted to account for associations with allogeneic stem cell transplantation, CMV and respiratory 454 
virus status
 
455 
j 
Adjusted to account for association with allogeneic stem cell transplantation, GVHD  and respiratory 456 
virus status
 
457 
k 
Adjusted to account for association with allogeneic stem cell transplantation, GVHD  and CMV 458 
status 459 
 460 
Key:  461 
NEF: No evidence of fungal infection CMV: Cytomegalovirus 462 
MDS: myelodysplastic syndrome RSV: Respiratory syncital virus 463 
GVHD: Graft versus host disease 464 
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Table 2. The prevalence of single nucleotide polymorphisms associated with invasive aspergillosis 465 
(IA) in haematology patients with EORTC-MSG defined proven/probable IA (n=54) and patients with 466 
no evidence of fungal disease (NEF, n=268). The prevalence of the SNP is based on a combined 467 
homozygous/heterozygous allele rate. Significant associations are shown in bold text with 468 
significance adjusted to P: 0.01 in accordance with the Bonferroni adjustment method. 469 
 
Gene 
 
Gene locus 
 
ABI-Assay 
Proven/Probable 
IA 
 
NEF 
Odds-ratio 
(95% CI) 
 
P value 
Dectin-1 rs16910526 C_33748481_10 12/54 51/268 1·2 (0·6-2·6) 0·576 
Dectin-1 rs7309123 C_3130832_10 47/54 173/268 3·7 (1·5-9·3) 0·001 
DC-SIGN rs11465384 C_25996399_10 15/54 30/268 3·1 (1·4-6·5) 0·004 
DC-SIGN rs7252229 C_29620333_10 17/54 55/268 1·8 (0·9-3·6) 0·106 
DC-SIGN rs7248637 C_29710787_10 18/54 37/268 2·9 (1·4-5·9)
a
 0·001
a 
Combination Haplotype and 
rs7309123 
C_3130832_10 
C_25996399_10 
C_29710787_10 
20/54 31/268 4.5 (2.2-9.2) <0.001 
 470 
a
 Adjusted for significant associations with AL/MDS. 471 
472 
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Table 3. The probability of invasive aspergillosis in the presence of clinical conditions and risk 473 
factors.  474 
Risk factor Percentage of population (n=322) Odds ratio (CI) Significance  (P value) 
AL/MDS 
a 
37·0% 2·1 (1·1-3·9) 0·011 
AL/MDS – Allo SCT + 
respiratory virus
b 
4·3% 4·2 (1·0-17·7) 0·036 
AL/MDS + Allo SCT
c 
6·2%  10·4 (3·2-35·1) <0·001 
AL/MDS + Allo SCT + 
respiratory virus
d 
2·8% 14·4 (1·1-412·5) 0·029 
Other 
e 
63·0% 0·5 (0·3-0·9) 0·011 
Other – Allo SCT + 
respiratory virus
f
 
4·7% 3·3 (0·6-15·7) 0·107 
Other + Allo SCT
g 
9·3%  7·6 (2·8-20·8) <0·001 
Other + Allo SCT + 
respiratory virus
h 
3·7% 4·0 (0·6-31·6) 0·127 
a 
Population used for analysis AL/MDS (N=119, 28 with IA) versus other haematological malignancy 475 
(N=203, 26 with IA). 476 
b 
Population used for analysis AL/MDS without allogeneic SCT but positive for respiratory virus 477 
infection (N= 14, 5 with IA) versus AL/MDS without allogeneic SCT and no evidence of respiratory 478 
virus infection (N=85, 10 with IA). 479 
c 
Population used for analysis AL/MDS with allogeneic SCT, (N=20, 13 with IA) versus AL/MDS 480 
without allogeneic SCT (N=99, 15 with IA). 481 
d 
Population used for analysis AL/MDS with allogeneic SCT with respiratory virus infection (N=9, 8 482 
with IA) versus AL/MDS without allogeneic SCT but with respiratory infection (N=14, 5 with IA). 483 
e 
Population used for analysis other haematological malignancy (N=203, 26 with IA) versus AL/MDS 484 
(N=119, 28 with IA).  485 
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f 
Population used for analysis other haematological malignancy without allogeneic SCT but positive 486 
for respiratory virus infection (N= 15, 3 with IA) versus other haematological malignancy without 487 
allogeneic SCT and no evidence of respiratory virus infection (N=158, 11 with IA). 488 
g 
Population used for analysis other haematological malignancy with allogeneic SCT, (N=30, 12 with 489 
IA) versus other haematological malignancy without allogeneic SCT (N=159, 14 with IA). 490 
h 
Population used for analysis other haematological malignancy with allogeneic SCT and respiratory 491 
virus infection (N=12, 6 with IA) versus other haematological malignancy without allogeneic SCT but 492 
with respiratory infection (N=15, 3 with IA). 493 
 494 
Key: 495 
AL/MDS: Acute leukaemia/myelodysplastic syndrome 496 
Allo SCT: Allogeneic stem cell transplantation 497 
Other: Includes Lymphoma, Myeloma, Chronic leukaemia, aplastic anaemia, myelofibrosis, 498 
unspecified leukaemia, Paroxysmal nocturnal hemoglobinuria, unspecified haematological 499 
malignancy, amyloidosis, unspecified autoimmune disorder, IGM paraproteinanaemia , and post 500 
transplant lymphoproliferative disorder. 501 
GVHD: Graft versus host disease.502 
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Figure 1a. The risk of IA associated with haematology patients not receiving, or prior, to allogeneic SCT (n=272) and the influence of genetic markers, 503 
respiratory virus infection and Aspergillus PCR result as determined by multi-logistic regression analysis. Percentage population (Pop) refers to the 504 
proportion of the total haematology cohort (n=322). PCR positivity was defined using a single PCR positive result as significant. 505 
 506 
 507 
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Figure 1b. The risk of IA associated with haematology patients receiving allogeneic SCT (n=50) and the influence of genetic markers, respiratory virus 508 
infection and Aspergillus PCR result as determined by multi-logistic regression analysis. Percentage population (Pop) refers to the proportion of the total 509 
haematology cohort (n=322). PCR positivity was defined using a single PCR positive result as significant. 510 
 511 
512 
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Figure 2. The distribution of risk of developing IA in a combined haematology population (n=322), 513 
haematology patient posts allogeneic stem cell transplantation (n=50) or haematology without 514 
allogeneic stem cell transplantation (n=272). 515 
  516 
 517 
 518 
 519 
 520 
 521 
 522 
 523 
 524 
525 
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Figure 3. Receiver Operator Characteristic Curve for the final predictive model containing allogeneic 526 
stem cell transplantation, single nucleotide polymorphisms in Dectin 1 and DC-SIGN haplotype, 527 
respiratory virus infection and Aspergillus PCR positivity as risk factors associated with developed 528 
invasive aspergillosis . The thresholds for determining sensitivity/specificity are as follows: 1) Only 529 
one variable positive, 2) two variables positive, 3) three variables positive, 4) four variables positive 530 
and 5) all variables positive. 531 
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Figure 4. Switches in allele type at the single nucleotide polymorphisms (SNPs) significantly associated 533 
with increased risk of developing IA 534 
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